Topas Therapeutics Topas Therapeutics Topas Therapeutics

Topas Therapeutics

Biopharma company - immunotherapy

Topas Therapeutics is a spin-off from Evotec, a leading global biopharmaceutical company, which together with partners is driving drug discovery and development at Topas. Topas has developed a unique technology to induce antigen-specific immune tolerance. This makes it possible to treat autoimmune diseases, allergies and drug-induced immune reactions more efficiently and safely. The company is currently conducting a phase 2 clinical trial in the field of coeliac disease.

Life Sciences

Visit website

Investment  details

Entry

2016

Staff

Location

Germany

At Topas Therapeutics, we're pioneering a game-changing approach to treat autoimmune disorders, allergies, and drug-induced immune reactions. Gimv's investment highlights our shared commitment to this innovative solution.

Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

Gimv has invested in Topas’s unique approach that has the potential to fundamentally change the treatment of autoimmune disorders.

Deal Team

Bram

Vanparys*

Managing Partner - Head Life Sciences

Belgium

Bram Vanparys*

Christoph

Kocher

Principal

Germany

Christoph Kocher

News News News

News

Portfolio